On June 24, 2024, Vico Therapeutics B.V. closed the transaction. The company raised ?11.5 million ($12.4 million) in its second and final tranche, bringing total funding raised in the transaction to ?65.8 million ($72.4 million) co-led by new investor, Seroba Life Sciences Limited and existing investor, Kurma Partners.